- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2017
- Public Summary Document (PSD) March 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2017 PBAC Meeting - Word
Ustekinumab – March 2017
Ustekinumab: Injection concentrate for I.V. infusion 130 mg in 26 mL, Injection 45 mg in 0.5 mL; Stelara®
Last updated
30 June 2017